Prolymphocytic Leukemia

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
1 program
1
sotrastaurin acetatePhase 21 trial
Active Trials
NCT02285244Withdrawn0Est. Mar 2015
Karyopharm Therapeutics
1 program
1
SelinexorPhase 11 trial
Active Trials
NCT02303392CompletedEst. Apr 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novartissotrastaurin acetate
Karyopharm TherapeuticsSelinexor

Clinical Trials (2)

NCT02285244Novartissotrastaurin acetate

Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation

Start: Mar 2015Est. completion: Mar 20150
Phase 2Withdrawn

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Start: Jun 2015Est. completion: Apr 2022
Phase 1Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space